Results 101 to 110 of about 13,154 (163)

Experience with ceftazidime–avibactam treatment in a tertiary care center in Saudi Arabia

Journal of Infection and Public Health, 2018
Introduction: Carbapenem-resistant organisms have become major healthcare-associated pathogens and are responsible for significant morbidity and mortality worldwide.
Abdullah Algwizani, Mohammad Alzunitan, Ahmad Alharbi, Abdulrahman Alsaedy, Sameera Aljohani, Bassam Alalwan, Jawaher Gramish, Adel Alothman   +7 more
doaj   +1 more source

Point prevalence surveys of antimicrobial use among eight neonatal intensive care units in India: 2016 [PDF]

, 2018
BACKGROUND: Information about antimicrobial use is scarce and poorly understood among neonatal intensive care units (NICUs) in India. In this study, we describe antimicrobial use in eight NICUs using four point prevalence surveys (PPSs). METHODS: As part
Akula, Akhila, Alvarez-Uria, Gerardo, Chikkappa, Ashok K., Dharmapalan, Dhanya, Gandra, Sumanth, Hsia, Yingfen, Hsia, Yingfen, Jinka, Dasaratha R., Kandraju, Hemasree, Kanithi, Ravishankar, Laxminarayan, Ramanan, Murki, Srinivas, Sharland, Mike, Sharma, Anita, Singh, Sanjeev K., Subramanian, Sreeram, Tunga, Onkaraiah, Vasudevan , Anil Kumar   +17 more
core   +2 more sources

Clin Infect Dis [PDF]

The dramatic increase in the prevalence and clinical impact of infections caused by bacteria producing carbapenemases is a global health concern.

core  

Role of Class I, II and III Integrons in Multidrug Resistance in Pseudomonas aeruginosa Isolated from Nosocomial Hospital [PDF]

, 2016
Aims: The increasing usage of antibiotics can cause resistance to the treatment of infections, which can caused by bacteria, e.g. Pseudomonas aeruginosa. The aim of this study was to trace the class I, II and III integrons in isolates of P. aeruginosa of
Momtaz, H., Nourbakhsh, F.
core   +1 more source

Antimicrobial Resistance (AMR) and Multidrug Resistance (MDR): Overview of Current Approaches, Consortia and Intellectual Property Issues [PDF]

, 2017
The supply of new diagnostics and treatments is insufficient to keep up with the increase in antimicrobial resistance (AMR) and multidrug resistance (MDR) as older medicines are used more widely and microbes develop resistance to them.
Bhagwandin, Niresh, Jenner, Andrew, Kowalski, Stanley P.   +2 more
core   +1 more source

AmpC β-lactamase induction by avibactam and relebactam [PDF]

, 2017
Background: Diazabicyclooctanes, e.g. avibactam and relebactam, are a new class of β-lactamase inhibitors. Their spectrum includes AmpC enzymes, but it is important to understand whether they also induce these enzymes.
Jamrozy, Dorota, Livermore, David M, Mushtaq, Shazad, Nichols, Wright W, Woodford, Neil, Young, Katherine   +5 more
core   +1 more source

Интраабдоминальная инфекция в свете последних международных рекомендаций и ее роль в развитии септической энцефалопатии [PDF]

, 2018
Цель данных рекомендаций: представить международную позицию, основанную на доказательствах, по вопросам тактики ведения интраабдоминальных инфекций и влияние интраабдоминальных инфекций на развитие септической энцефалопатии.
Лисничая, В.Н., Мальцева, Л.А., Мосенцев, Н.Ф.   +2 more
core  

Suboptimal ceftazidime-avibactam exposure drives sequential blaKPC mutations and intra-host coexistence of Klebsiella pneumoniae harboring distinct variants leading to persistent infection

Microbiology Spectrum
KPC-producing Klebsiella pneumoniae infections are a rising global health threat. The factors driving blaKPC mutations during treatment and their contribution to infection persistence remain unclear.
Feng Yang, Weiwei Yang, Jinghao Zhang, Chengkang Tang, Li Ding, Siquan Shen, Yanhao Zhou, Hongyu Zhao, Jiaojiao Zhou, Fupin Hu   +9 more
doaj   +1 more source

In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies [PDF]

We described the emergence of ceftazidime/avibactam and cefiderocol cross-resistance in patients with KPC-producing Klebsiella pneumoniae infections. All strains with ceftazidime/avibactam and cefiderocol cross-resistance showed point mutations on KPC Ω ...
Amadesi S., Amedeo A., Gaibani P., Giannella M., Palombo M., Rinaldi M.   +5 more
core   +1 more source

Diverse evolutionary trajectories of Klebsiella pneumoniae carbapenemase: unraveling the impact of amino acid substitutions on β-lactam susceptibility and the role of avibactam in driving resistance

mSystems
Klebsiella pneumoniae carbapenemases (KPCs) have evolved into over 245 distinct variants, with over one-third of variants exhibiting reduced susceptibility to ceftazidime-avibactam, while the underlying selection mechanisms remain elusive.
Jie Wei, Jinyu Huang, Chunhong Zou, Shimei Shen, Barry N. Kreiswirth, Ailong Huang, Shifeng Huang, Liang Chen, Deqiang Wang, Siqiang Niu   +9 more
doaj   +1 more source